Repare Therapeutics Inc (RPTX) - Total Assets
Based on the latest financial reports, Repare Therapeutics Inc (RPTX) holds total assets worth $126.75 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See RPTX book value for net asset value and shareholders' equity analysis.
Repare Therapeutics Inc - Total Assets Trend (2018–2024)
This chart illustrates how Repare Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Repare Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Repare Therapeutics Inc's total assets of $126.75 Million consist of 97.0% current assets and 3.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 48.0% |
| Accounts Receivable | $12.35 Million | 7.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Repare Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Repare Therapeutics Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Repare Therapeutics Inc's current assets represent 97.0% of total assets in 2024, an increase from 86.5% in 2018.
- Cash Position: Cash and equivalents constituted 48.0% of total assets in 2024, down from 77.1% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 7.0% of total assets.
Repare Therapeutics Inc Competitors by Total Assets
Key competitors of Repare Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Repare Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.71 | 6.45 | 31.46 |
| Quick Ratio | 10.71 | 6.55 | 31.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $112.81 Million | $169.32 Million | $335.54 Million |
Repare Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Repare Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.99 |
| Latest Market Cap to Assets Ratio | 0.65 |
| Asset Growth Rate (YoY) | -30.5% |
| Total Assets | $176.51 Million |
| Market Capitalization | $114.24 Million USD |
Valuation Analysis
Below Book Valuation: The market values Repare Therapeutics Inc's assets below their book value (0.65x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Repare Therapeutics Inc's assets decreased by 30.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Repare Therapeutics Inc (2018–2024)
The table below shows the annual total assets of Repare Therapeutics Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $176.51 Million | -30.48% |
| 2023-12-31 | $253.90 Million | -30.26% |
| 2022-12-31 | $364.07 Million | -1.26% |
| 2021-12-31 | $368.71 Million | +3.26% |
| 2020-12-31 | $357.09 Million | +247.72% |
| 2019-12-31 | $102.69 Million | +637.49% |
| 2018-12-31 | $13.93 Million | -- |
About Repare Therapeutics Inc
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camo… Read more